| Identification | Back Directory | [Name]
KIT/PDGFR inhibitor(DCC2618) | [CAS]
1442472-39-0 | [Synonyms]
Ripretinib
KIT/PDGFR inhibitor
Ripretinib USP/EP/BP
Ripretinib (DCC-2618)
KIT/PDGFR inhibitor(DCC2618)
DCC-2618;KIT/PDGFR INHIBITOR
KIT/PDGFR INHIBITOR(DCC-2618)
DCC-2618; DCC 2618; DCC2618; RIPRETINIB;
1-(4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl)-3-phenylurea
N-[4-Bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenylurea
Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl- | [Molecular Formula]
C24H21BrFN5O2 | [MDL Number]
MFCD31657437 | [MOL File]
1442472-39-0.mol | [Molecular Weight]
510.36 |
| Chemical Properties | Back Directory | [Boiling point ]
568.6±50.0 °C(Predicted) | [density ]
1.544±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:25.0(Max Conc. mg/mL);49.0(Max Conc. mM) | [form ]
A solid | [pka]
12.15±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
Ripretinib is used in the treatment of gastrointestinal stromal tumors (GISTs). | [Brand name]
Qinlock | [General Description]
Class: receptor tyrosine kinase;
Treatment: GIST;
Other name: DCC-2618;
Elimination half-life = 15 h;
Protein binding = 98.8% | [Biological Activity]
Ripretinib is a highly effective inhibitor of both wild-type KIT and PDGFRA, with IC50 values around 3 nM. It also targets a wide range of KIT and PDGFRA mutants in GIST. Additionally, it inhibits various tumor-driving kinases such as PDGFRβ, TIE2, VEGFR2, and BRAF. | [target]
Primary targets: PDGFRA, KIT |
|
|